DMAC Competitors & Alternatives
Compare DiaMedica Therapeutics Inc with similar stocks in the same industry
Biotechnology
DMAC
Main Stock$8.42
-4.27%
Tradestie Score
48
Market Cap
$354.59M
Analyst Upside
+84.2%
Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)
Bottleneck Score: 2/10
Drug Discovery Biotech
Drug Design
Top Competitors
221 stocks in Biotechnology| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
VSTM
Verastem, Inc.
|
$7.88
-3.67%
|
$541.60M | - | 54 | Compare |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
$10.55
-0.85%
|
$540.97M | - | 34 | Compare |
|
ZVRA
Zevra Therapeutics, Inc. Common Stock
|
$9.31
+2.53%
|
$529.35M | 9.7 | 56 | Compare |
|
LXRX
Lexicon Pharmaceuticals, Inc.
|
$1.75
-2.51%
|
$512.39M | - | 37 | Compare |
|
RIGL
Rigel Pharmaceuticals Inc. (New)
|
$43.73
-1.64%
|
$505.12M | 2.8 | 54 | Compare |
|
RGNX
REGENXBIO Inc.
|
$7.47
-2.23%
|
$493.52M | - | 44 | Compare |
|
INBX
Inhibrx Biosciences, Inc. Common Stock
|
$77.32
-7.18%
|
$492.21M | - | 49 | Compare |
|
XOMA
XOMA Royalty Corporation Common Stock
|
$40.17
-9.16%
|
$474.20M | 28.2 | 46 | Compare |
|
ABSI
Absci Corporation Common Stock
|
$7.73
-8.58%
|
$468.01M | - | 44 | Compare |
|
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
|
$9.11
-2.77%
|
$463.20M | - | 44 | Compare |
More DMAC Analysis
Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2834)
221 stocks in this industry